Ixabepilone and Ketoconazole in Treating Patients With Advanced Solid Tumors
RATIONALE: Drugs used in chemotherapy, such as ixabepilone and ketoconazole, work in different ways to stop tumor cells from dividing so they stop growing or die. Giving ixabepilone with ketoconazole may kill more tumor cells.
PURPOSE: This phase I/II trial is studying the side effects and best dose of giving ixabepilone together with ketoconazole and to see how well they work in treating patients with advanced solid tumors.
Unspecified Adult Solid Tumor, Protocol Specific
|Study Design:||Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Effect Of Ketoconazole On The Pharmacokinetics Of BMS-247550 In Patients With Advanced Cancer|
- Effect of ketoconazole on the pharmacokinetics of ixabepilone [ Designated as safety issue: No ]
- Safety of ixabepilone with and without ketoconazole [ Designated as safety issue: Yes ]
- Antitumor activity [ Designated as safety issue: No ]
|Study Start Date:||March 2003|
- Determine the effect of ketoconazole on the pharmacokinetics of ixabepilone in patients with advanced solid tumors.
- Determine the safety of ixabepilone when administered alone and in combination with ketoconazole in these patients.
- Determine, preliminarily, the antitumor activity of this regimen in these patients.
OUTLINE: This is an open-label, dose-escalation study of ixabepilone.
During course 1, patients receive oral ketoconazole on days 0-5 and ixabepilone IV over 3 hours on day 1. During course 2 and subsequent courses, patients receive only ixabepilone IV over 3 hours on day 1. Courses repeat every 21 days in the absence of disease progression or unacceptable toxicity.
Cohorts of at least 3 patients receive escalating doses of ixabepilone during course 1 until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 patients experience dose-limiting toxicity. At least 12 patients are treated at the MTD.
PROJECTED ACCRUAL: A total of 3-35 patients will be accrued for this study.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00096317
|United States, New York|
|Albert Einstein Cancer Center at Albert Einstein College of Medicine|
|Bronx, New York, United States, 10461|
|Study Chair:||Sridhar Mani, MD||Albert Einstein College of Medicine of Yeshiva University|